Laboratory Medicine ›› 2015, Vol. 30 ›› Issue (8): 804-807.DOI: 10.3969/j.issn.1673-8640.2015.08.007
Previous Articles Next Articles
Received:2014-10-09
Online:2015-08-30
Published:2015-08-28
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2015.08.007
| 组别 | 例数(%) | 年龄(岁) | 男性例数(%) | 高血压[例(%)] | TC(mmol/L) | ||||
|---|---|---|---|---|---|---|---|---|---|
| 体重过低组 | 169 | (5.93) | 39.0±16.4 | 61(39.1) | 11 | (6.5) | 4.87±0.90 | ||
| 体重正常组 | 1 491 | (52.3) | 47.8±13.9 | 700(46.9) | 229 | (15.4) | 5.19±0.98 | ||
| 超重组 | 972 | (34.1) | 51.2±13.2** | 666(68.5)** | 266 | (27.4)** | 5.37±0.99** | ||
| 肥胖组 | 217 | (7.62) | 50.4±14.9** | 142(65.4)** | 86 | (39.6)** | 5.45±1.09** | ||
| 合计 | 2 849 | 48.6±14.2 | 1 569(55.1) | 592 | (20.8) | 5.25±1.00 | |||
| 组别 | TG(mmol/L) | Glu(mmol/L) | UA(μmol/L) | PGⅠ(μg/L) | |||||
| 体重过低组 | 0.87±0.48 | 5.02±1.92 | 292.0±81.3 | 101.93±45.12* | |||||
| 体重正常组 | 1.22±0.87 | 5.21±1.21 | 322.0±82.7 | 110.51±50.10 | |||||
| 超重组 | 1.69±1.05** | 5.47±1.43** | 378.0±89.9** | 106.14±44.96* | |||||
| 肥胖组 | 2.13±1.96** | 5.86±1.91** | 394.0±88.8** | 100.93±45.49* | |||||
| 合计 | 1.43±1.08 | 5.34±1.37 | 345.0±91.1 | 107.80±47.90 | |||||
| 组别 | PGⅡ (μg/L) | PGⅠ/PGⅡ 比值 | 用药史 [例(%)] | 既往史[例(%)] | |||||
| 消化道溃疡 | 胃炎 | ||||||||
| 体重过低组 | 13.24±8.66 | 9.50±4.42 | 5 | (3.0) | 3(2.0) | 16(9.4) | |||
| 体重正常组 | 13.72±9.70 | 9.81±4.19 | 115 | (7.8) | 30(2.0) | 112(7.5) | |||
| 超重组 | 12.74±8.48 | 10.19±4.64 | 148 | (15.2)** | 17(1.7) | 62(6.6) | |||
| 肥胖组 | 12.15±8.13 | 10.08±4.42 | 35 | (16.1)** | 2(0.9) | 6(2.8) | |||
| 合计 | 13.24±9.13 | 9.95±4.38 | 303 | (10.6) | 52(1.8) | 196(6.9) | |||
| 组别 | 例数(%) | 年龄(岁) | 男性例数(%) | 高血压[例(%)] | TC(mmol/L) | ||||
|---|---|---|---|---|---|---|---|---|---|
| 体重过低组 | 169 | (5.93) | 39.0±16.4 | 61(39.1) | 11 | (6.5) | 4.87±0.90 | ||
| 体重正常组 | 1 491 | (52.3) | 47.8±13.9 | 700(46.9) | 229 | (15.4) | 5.19±0.98 | ||
| 超重组 | 972 | (34.1) | 51.2±13.2** | 666(68.5)** | 266 | (27.4)** | 5.37±0.99** | ||
| 肥胖组 | 217 | (7.62) | 50.4±14.9** | 142(65.4)** | 86 | (39.6)** | 5.45±1.09** | ||
| 合计 | 2 849 | 48.6±14.2 | 1 569(55.1) | 592 | (20.8) | 5.25±1.00 | |||
| 组别 | TG(mmol/L) | Glu(mmol/L) | UA(μmol/L) | PGⅠ(μg/L) | |||||
| 体重过低组 | 0.87±0.48 | 5.02±1.92 | 292.0±81.3 | 101.93±45.12* | |||||
| 体重正常组 | 1.22±0.87 | 5.21±1.21 | 322.0±82.7 | 110.51±50.10 | |||||
| 超重组 | 1.69±1.05** | 5.47±1.43** | 378.0±89.9** | 106.14±44.96* | |||||
| 肥胖组 | 2.13±1.96** | 5.86±1.91** | 394.0±88.8** | 100.93±45.49* | |||||
| 合计 | 1.43±1.08 | 5.34±1.37 | 345.0±91.1 | 107.80±47.90 | |||||
| 组别 | PGⅡ (μg/L) | PGⅠ/PGⅡ 比值 | 用药史 [例(%)] | 既往史[例(%)] | |||||
| 消化道溃疡 | 胃炎 | ||||||||
| 体重过低组 | 13.24±8.66 | 9.50±4.42 | 5 | (3.0) | 3(2.0) | 16(9.4) | |||
| 体重正常组 | 13.72±9.70 | 9.81±4.19 | 115 | (7.8) | 30(2.0) | 112(7.5) | |||
| 超重组 | 12.74±8.48 | 10.19±4.64 | 148 | (15.2)** | 17(1.7) | 62(6.6) | |||
| 肥胖组 | 12.15±8.13 | 10.08±4.42 | 35 | (16.1)** | 2(0.9) | 6(2.8) | |||
| 合计 | 13.24±9.13 | 9.95±4.38 | 303 | (10.6) | 52(1.8) | 196(6.9) | |||
| 变量 | PGⅠ | PGⅠ/PGⅡ比值 | |||||
|---|---|---|---|---|---|---|---|
| β值 | Beta | P值 | β值 | Beta | P值 | ||
| 性别(男) | -15.028 | -0.156 | <0.001 | -0.937 | -0.106 | <0.001 | |
| 年龄 | 0.552 | 0.164 | <0.001 | -0.056 | -0.182 | <0.001 | |
| BMI | -1.232 | -0.083 | <0.001 | 0.180 | 0.032 | 0.114 | |
| 高血压 | -4.650 | -0.039 | 0.047 | -0.202 | -0.020 | 0.337 | |
| Glu | 0.166 | 0.005 | 0.806 | 0.155 | 0.049 | 0.011 | |
| TC | 1.291 | 0.027 | 0.154 | -0.027 | -0.007 | 0.729 | |
| TG | 0.055 | 0.002 | 0.909 | 0.180 | 0.044 | 0.020 | |
| UA | 0.003 | 0.007 | 0.777 | 0.00 | -0.017 | 0.481 | |
| 药物史 | 2.590 | 0.017 | 0.410 | 0.721 | 0.048 | 0.009 | |
| 既往史 | 2.728 | 0.017 | 0.366 | 0.702 | 0.049 | 0.012 | |
| 变量 | PGⅠ | PGⅠ/PGⅡ比值 | |||||
|---|---|---|---|---|---|---|---|
| β值 | Beta | P值 | β值 | Beta | P值 | ||
| 性别(男) | -15.028 | -0.156 | <0.001 | -0.937 | -0.106 | <0.001 | |
| 年龄 | 0.552 | 0.164 | <0.001 | -0.056 | -0.182 | <0.001 | |
| BMI | -1.232 | -0.083 | <0.001 | 0.180 | 0.032 | 0.114 | |
| 高血压 | -4.650 | -0.039 | 0.047 | -0.202 | -0.020 | 0.337 | |
| Glu | 0.166 | 0.005 | 0.806 | 0.155 | 0.049 | 0.011 | |
| TC | 1.291 | 0.027 | 0.154 | -0.027 | -0.007 | 0.729 | |
| TG | 0.055 | 0.002 | 0.909 | 0.180 | 0.044 | 0.020 | |
| UA | 0.003 | 0.007 | 0.777 | 0.00 | -0.017 | 0.481 | |
| 药物史 | 2.590 | 0.017 | 0.410 | 0.721 | 0.048 | 0.009 | |
| 既往史 | 2.728 | 0.017 | 0.366 | 0.702 | 0.049 | 0.012 | |
| 变量 | β值 | OR值 | 95%可信区间 | P值 |
|---|---|---|---|---|
| BMI分级(kg/m2) | ||||
| <18.5 | -0.050 | 1.011 | 0.669~1.528 | 0.790 |
| 18.5~23.9 | - | 1.000 | - | - |
| 24.0~27.9 | 0.161 | 1.175 | 0.963~1.434 | 0.113 |
| ≥28.0 | 0.520 | 1.682 | 1.220~2.317 | 0.001 |
| 年龄 | -0.012 | 0.990 | 0.983~0.997 | <0.001 |
| 女性 | 0.581 | 1.827 | 1.496~2.233 | <0.001 |
| 变量 | β值 | OR值 | 95%可信区间 | P值 |
|---|---|---|---|---|
| BMI分级(kg/m2) | ||||
| <18.5 | -0.050 | 1.011 | 0.669~1.528 | 0.790 |
| 18.5~23.9 | - | 1.000 | - | - |
| 24.0~27.9 | 0.161 | 1.175 | 0.963~1.434 | 0.113 |
| ≥28.0 | 0.520 | 1.682 | 1.220~2.317 | 0.001 |
| 年龄 | -0.012 | 0.990 | 0.983~0.997 | <0.001 |
| 女性 | 0.581 | 1.827 | 1.496~2.233 | <0.001 |
| [1] | ZHENG W,MCLERRAN DF,ROLLAND B,et al.Association between body-mass index and risk of death in more than 1 million Asians[J].N Engl J Med,2011,364(8) :719-729. |
| [2] | RENEHAN AG,TYSON M,EGGER M,et al.Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies[J]. Lancet,2008,371(9612) :569-578. |
| [3] | YANG P,ZHOU Y,CHEN B,et al.Overweight,obesity and gastric cancer risk:results from a meta-analysis of cohort studies[J]. Eur J Cancer,2009,45(16):2867-2873. |
| [4] | 张金锋. 血清胃蛋白酶原、CEA、CA19-9及CA72-4检测对胃癌的诊断价值探讨[J]. 检验医学,2014,29(8):831-834. |
| [5] | 邬建民,张力. 血清胃蛋白酶原、胃泌素-17和幽门螺杆菌IgG抗体对萎缩性胃炎的诊断价值[J]. 检验医学,2011,26(6):375-378. |
| [6] | FOCK KM,TALLEY N,MOAYYEDI P,et al.Asia-Pacific consensus guidelines on gastric cancer prevention[J]. J Gastroenterol Hepatol,2008,23(3):351-365. |
| [7] | ZHENG KC,AOKI K,LI XQ,et al.Serum pepsinogens,gastrin-17 and Helicobacter pylori antibody in the residents of two cities in china with distinct mortality rates of gastric cancer[J]. Tohoku J Exp Med,2012,228(4):289-294. |
| [8] | HUANG M,TANG AG,MU S,et al.Serum pepsinogen reference intervals in apparently healthy Chinese population with latex enhanced turbidimetric immuno-assay[J]. J Clin Pathol,2014,67(4):350-354. |
| [9] | ZHANG XM,LI JX,ZHANG GY,et al.The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China[J]. BMC Gastroenterol,2014,14:3. |
| [10] | CSENDES A,BURGOS AM,SMOK G,et al.Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity[J]. Obes Surg,2007,17(1):28-34. |
| [11] | GAO L,WECK MN,ROTHENBACHER D, et al.Body mass index,chronic atrophic gastritis and heartburn:a population-based study among 8 936 older adults from Germany[J]. Aliment Pharmacol Ther,2010,32(2):296-302. |
| [12] | YAMAMOTO S,WATABE K,TSUTSUI S,et al.Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis[J]. Dig Dis Sci,2011,56(8):2354-2360. |
| [13] | EL-HAGGAR SM, MOSTAFA TM.Adipokines and biochemical changes in Egyptian obese subjects: possible variation with sex and degree of obesity[J]. Endocrine, 2015, 48(3): 878-885. |
| [14] | AL-HAMODI Z, AL-HABORI M, AL-MEERI A, et al.Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2014,6(1): 99. |
| [15] | TORISU T,MATSUMOTO T,TAKATA Y,et al.Atrophic gastritis,but not antibody to Helicobacter pylori,is associated with body mass index in a Japanese population[J]. J Gastroenterol,2008,43(10):762-766. |
| [16] | WATABE H,MITSUSHIMA T,DERAKHSHAN MH,et al.Study of association between atrophic gastritis and body mass index:a cross-sectional study in 10 197 Japanese subjects[J]. Dig Dis Sci,2009,54(5):988-995. |
| [17] | KUTSUMA A,OSHIDA H,SUWA K,et al.A possible association of low pepsinogen I and pepsinogen Ⅰ/Ⅱ with low and high body weight in Japanese men[J]. Clin Biochem,2014,47(1-2):126-128. |
| [18] | TANAKA M,FUKUI M,KURODA M,et al.Pepsinogen Ⅰ/Ⅱ ratio is related to glucose,triacylglycerol,and uric acid levels[J].Nutrition,2012,28(4):418-421. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
